FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Phase 1

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Stage III Lung Non-Small Cell Cancer AJCC v7
Recurrent Acute Lymphoblastic Leukemia
Recurrent Mantle Cell Lymphoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Unresectable Lung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Lung Non-Small Cell Carcinoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Biological: ROR1 CAR-specific Autologous T-Lymphocytes

First Posted Date: 2016-03-11

Last Posted Date: 2022-08-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT02706392

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
Drug: Cyclophosphamide
Biological: Durvalumab
Drug: Fludarabine

First Posted Date: 2016-03-11

Last Posted Date: 2022-08-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02706405

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

Not Applicable

Completed

Conditions: Insulin Resistance
Metabolic Syndrome
Obesity
Diabetes
NAFLD
Inflammation

Interventions: Other: Limited dairy diet
Other: Full-fat dairy diet
Other: Low-fat dairy diet

First Posted Date: 2016-01-26

Last Posted Date: 2019-01-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 72

Registration Number: NCT02663544

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Idelalisib

First Posted Date: 2016-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02662296

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Cancer Survivor
Stage IA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage 0 Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer

Interventions: Other: Computer-Assisted Cognitive Training
Other: Questionnaire Administration
Procedure: Standard Follow-Up Care

First Posted Date: 2016-01-25

Last Posted Date: 2017-12-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02662335

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Hypnotherapy in Treating Chronic Pain in Cancer Survivors

Not Applicable

Completed

Conditions: Anxiety
Cancer Survivor
Depression
Chronic Pain
Sleep Disorder

Interventions: Other: Questionnaire Administration
Procedure: Hypnotherapy

First Posted Date: 2015-12-22

Last Posted Date: 2017-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 39

Registration Number: NCT02637297

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma
Transplant-Related Carcinoma

Interventions: Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2015-12-02

Last Posted Date: 2024-04-25

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02619682

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

Phase 1

Terminated

Conditions: Stage IV Merkel Cell Carcinoma AJCC v7
Merkel Cell Polyomavirus Infection

Interventions: Drug: Avelumab
Other: Laboratory Biomarker Analysis
Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Radiation: Radiation Therapy
Biological: Recombinant Interferon Beta

First Posted Date: 2015-10-23

Last Posted Date: 2022-03-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8

Registration Number: NCT02584829

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

HSV529 Vaccine in HSV-2 Seropositive Adults

Phase 1

Completed

Conditions: Herpes Simplex Virus 2

Interventions: Biological: HSV529
Drug: Valacyclovir

First Posted Date: 2015-10-08

Last Posted Date: 2019-01-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 10

Registration Number: NCT02571166

Locations: 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States

Meals and Grazing Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: High Eating Frequency (High EF)
Behavioral: Low Eating Frequency (Low EF)

First Posted Date: 2015-09-14

Last Posted Date: 2015-09-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02548026

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy